Scynexis Inc (SCYX): Cash & Equivalents
$21.26M
As of 2025-12-31
$10.49M
As of 2026-06-30
-22.6%
3-year compound annual growth
-25.6%
5-year compound annual growth
-7.6%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $21.26M | +32.4% | 2026-03-04, Balance as of period end |
| 2024-12-31 | $16.05M | -52.9% | 2026-03-04, Balance as of period end |
| 2023-12-31 | $34.05M | -25.7% | 2025-03-12, Balance as of period end |
| 2022-12-31 | $45.81M | -56.2% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $104.48M | +12.3% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $93.04M | +121.9% | 2022-03-29, Balance as of period end |
| 2019-12-31 | $41.92M | +266.5% | 2021-03-29, Balance as of period end |
| 2018-12-31 | $11.44M | -0.3% | 2020-03-11, Balance as of period end |
| 2017-12-31 | $11.47M | -67.8% | 2019-03-14, Balance as of period end |
| 2016-12-31 | $35.66M | -24.1% | 2018-03-13, Balance as of period end |
| 2015-12-31 | $46.98M | +45.7% | 2017-03-13, Balance as of period end |
| 2014-12-31 | $32.24M | n/m | 2017-03-13, Balance as of period end |
| 2013-12-31 | $1.40M | n/a | 2015-03-30, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Scynexis Inc (SCYX) | 2025-12-31 | $21.26M | +32.4% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $5.63M | -58.2% |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | $578.0K | -22.0% |
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $11.03M | -43.4% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $490.00M | -36.5% |
| Alumis Inc. (ALMS) | 2025-12-31 | $89.67M | -47.1% |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $90.39M | -10.7% |
| uniQure N.V. (QURE) | 2025-12-31 | $80.24M | -49.5% |
| Celularity Inc (CELU) | 2025-12-31 | $6.17M | +736.7% |
Compare SCYX, CASIF, EVFM, SLGL side by side · Screen every company in Pharmaceutical Preparations ↗